Copyright
©2010 Baishideng Publishing Group Co.
World J Gastroenterol. Sep 21, 2010; 16(35): 4400-4409
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Published online Sep 21, 2010. doi: 10.3748/wjg.v16.i35.4400
Male | Female | Total | ||||
n | SVR | n | SVR | n | SVR | |
Group A | ||||||
Minimum acceptable | 168 | 116 (69.0) | 110 | 69 (62.7) | 278 | 185 (66.5) |
Reduced | 206 | 73 (35.4) | 201 | 66 (32.8) | 407 | 139 (34.2) |
Total | 374 | 189 (50.5) | 311 | 135 (43.4) | 685 | 324 (47.3) |
Group B | ||||||
Minimum acceptable | 31 | 15 (48.4) | 31 | 13 (41.9) | 62 | 28 (45.2) |
Reduced | 91 | 18 (19.8) | 100 | 12 (12.0) | 191 | 30 (15.7) |
Total | 122 | 33 (27.0) | 131 | 25 (19.1) | 253 | 58 (22.9) |
- Citation: Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, Satoh T, Maruyama T, Nakamuta M, Kotoh K, Azuma K, Shimono J, Shimoda S, Hayashi J, Group TKULDS. Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16(35): 4400-4409
- URL: https://www.wjgnet.com/1007-9327/full/v16/i35/4400.htm
- DOI: https://dx.doi.org/10.3748/wjg.v16.i35.4400